{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,12]],"date-time":"2026-11-12T10:26:52Z","timestamp":1794479212852,"version":"4.9.1"},"reference-count":65,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Neuropharmacology"],"published-print":{"date-parts":[[2026,9]]},"DOI":"10.1016\/j.neuropharm.2026.110994","type":"journal-article","created":{"date-parts":[[2026,4,28]],"date-time":"2026-04-28T22:02:26Z","timestamp":1777413746000},"page":"110994","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Unexpected mechanisms of repurposed drugs in the pathogenic pathways of neurodegenerative diseases. Discovering new neuroprotective therapies in cellular models"],"prefix":"10.1016","volume":"295","author":[{"ORCID":"https:\/\/orcid.org\/0009-0002-3144-5769","authenticated-orcid":false,"given":"M.S.","family":"Arasmou-Idrovo","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"B.","family":"Mar\u00edn-Rodr\u00edguez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9707-9277","authenticated-orcid":false,"given":"A.","family":"Gironda-Mart\u00ednez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.G.","family":"Garc\u00eda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R.","family":"Le\u00f3n","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6667-3310","authenticated-orcid":false,"given":"J.","family":"Pascual-Guerra","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Torres-Rico","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.neuropharm.2026.110994_bib1","doi-asserted-by":"crossref","DOI":"10.3389\/fnagi.2024.1347987","article-title":"The role of neuroinflammation in neurodegenerative diseases: current understanding and future therapeutic targets","volume":"16","author":"Adamu","year":"2024","journal-title":"Front. Aging Neurosci."},{"issue":"3","key":"10.1016\/j.neuropharm.2026.110994_bib2","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1038\/nrd1330","article-title":"Neurodegenerative diseases and oxidative stress","volume":"3","author":"Barnham","year":"2004","journal-title":"Nat. Rev. Drug Discov."},{"issue":"15","key":"10.1016\/j.neuropharm.2026.110994_bib3","doi-asserted-by":"crossref","DOI":"10.3390\/cells13151301","article-title":"Calcium deregulation in neurodegeneration and neuroinflammation in Parkinson's disease: role of calcium-storing organelles and sodium-calcium exchanger","volume":"13","author":"Bastioli","year":"2024","journal-title":"Cells"},{"issue":"3","key":"10.1016\/j.neuropharm.2026.110994_bib4","doi-asserted-by":"crossref","first-page":"624","DOI":"10.1111\/bph.12314","article-title":"Pharmacological characterization of a novel centrally permeable P2X7 receptor antagonist: JNJ-47965567","volume":"170","author":"Bhattacharya","year":"2013","journal-title":"Br. J. Pharmacol."},{"issue":"1","key":"10.1016\/j.neuropharm.2026.110994_bib5","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1016\/S0165-0327(00)00199-3","article-title":"Antioxidative enzyme activities and lipid peroxidation in major depression: alterations by antidepressant treatments","volume":"64","author":"Bilici","year":"2001","journal-title":"J. Affect. Disord."},{"issue":"2","key":"10.1016\/j.neuropharm.2026.110994_bib6","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1016\/S0301-0082(01)00003-X","article-title":"Molecular pathways involved in the neurotoxicity of 6-OHDA, dopamine and MPTP: contribution to the apoptotic theory in Parkinson's disease","volume":"65","author":"Blum","year":"2001","journal-title":"Prog. Neurobiol."},{"issue":"1","key":"10.1016\/j.neuropharm.2026.110994_bib7","doi-asserted-by":"crossref","DOI":"10.2196\/14232","article-title":"Molecular docking using chimera and autodock Vina software for nonbioinformaticians","volume":"1","author":"Butt","year":"2020","journal-title":"JMIR Bioinform. Biotechnol."},{"key":"10.1016\/j.neuropharm.2026.110994_bib8","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/0065-2571(84)90007-4","article-title":"Quantitative analysis of dose-effect relationships: the combined effects of multiple drugs or enzyme inhibitors","volume":"22","author":"Chou","year":"1984","journal-title":"Adv. Enzym. Regul."},{"issue":"32","key":"10.1016\/j.neuropharm.2026.110994_bib9","doi-asserted-by":"crossref","first-page":"3765","DOI":"10.1038\/onc.2012.388","article-title":"Nrf2 is controlled by two distinct beta-TrCP recognition motifs in its Neh6 domain, one of which can be modulated by GSK-3 activity","volume":"32","author":"Chowdhry","year":"2013","journal-title":"Oncogene"},{"issue":"4","key":"10.1016\/j.neuropharm.2026.110994_bib10","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1016\/j.tips.2005.02.007","article-title":"The efficiency of multi-target drugs: the network approach might help drug design","volume":"26","author":"Csermely","year":"2005","journal-title":"Trends Pharmacol. Sci."},{"issue":"4","key":"10.1016\/j.neuropharm.2026.110994_bib11","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1038\/s41573-018-0008-x","article-title":"Therapeutic targeting of the NRF2 and KEAP1 partnership in chronic diseases","volume":"18","author":"Cuadrado","year":"2019","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.neuropharm.2026.110994_bib12","doi-asserted-by":"crossref","DOI":"10.1155\/2013\/839409","article-title":"Mechanisms of Nrf2\/Keap1-dependent phase II cytoprotective and detoxifying gene expression and potential cellular targets of chemopreventive isothiocyanates","volume":"2013","author":"Das","year":"2013","journal-title":"Oxid. Med. Cell. Longev."},{"issue":"2","key":"10.1016\/j.neuropharm.2026.110994_bib13","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1111\/j.1755-5949.2008.00067.x","article-title":"Vilazodone: a 5-HT1A receptor agonist\/serotonin transporter inhibitor for the treatment of affective disorders","volume":"15","author":"Dawson","year":"2009","journal-title":"CNS Neurosci. Ther."},{"issue":"8","key":"10.1016\/j.neuropharm.2026.110994_bib14","doi-asserted-by":"crossref","first-page":"C643","DOI":"10.1152\/ajpcell.00007.2016","article-title":"Molecular mechanisms of STIM\/Orai communication","volume":"310","author":"Derler","year":"2016","journal-title":"Am. J. Physiol. Cell Physiol."},{"issue":"4","key":"10.1016\/j.neuropharm.2026.110994_bib15","first-page":"1465","article-title":"Mechanistic approach for thioridazine-induced hepatotoxicity and potential benefits of Melatonin and\/or Coenzyme Q10 on freshly isolated rat hepatocytes","volume":"17","author":"Eftekhari","year":"2018","journal-title":"Iran. J. Pharm. Res."},{"issue":"2","key":"10.1016\/j.neuropharm.2026.110994_bib16","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pcbi.1008686","article-title":"SAveRUNNER: a network-based algorithm for drug repurposing and its application to COVID-19","volume":"17","author":"Fiscon","year":"2021","journal-title":"PLoS Comput. Biol."},{"issue":"10","key":"10.1016\/j.neuropharm.2026.110994_bib18","doi-asserted-by":"crossref","DOI":"10.3390\/jpm12101731","article-title":"Identification of potential repurposable drugs in Alzheimer's Disease exploiting a bioinformatics analysis","volume":"12","author":"Fiscon","year":"2022","journal-title":"J. Personalized Med."},{"issue":"1","key":"10.1016\/j.neuropharm.2026.110994_bib17","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1186\/s12859-021-04076-w","article-title":"SAveRUNNER: an R-based tool for drug repurposing","volume":"22","author":"Fiscon","year":"2021","journal-title":"BMC Bioinf."},{"issue":"W1","key":"10.1016\/j.neuropharm.2026.110994_bib19","doi-asserted-by":"crossref","first-page":"W422","DOI":"10.1093\/nar\/gkae236","article-title":"ADMETlab 3.0: an updated comprehensive online ADMET prediction platform enhanced with broader coverage, improved performance, API functionality and decision support","volume":"52","author":"Fu","year":"2024","journal-title":"Nucleic Acids Res."},{"issue":"1","key":"10.1016\/j.neuropharm.2026.110994_bib20","first-page":"103","article-title":"The effects of propranolol metipranolol, and pindolol on the cardiovascular system of rabbits in vivo","volume":"27","author":"Gersl","year":"1984","journal-title":"Sb Ved Pr Lek Fak Karlovy Univerzity Hradci Kralove"},{"issue":"3","key":"10.1016\/j.neuropharm.2026.110994_bib21","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1002\/prot.340080302","article-title":"Automated docking of substrates to proteins by simulated annealing","volume":"8","author":"Goodsell","year":"1990","journal-title":"Proteins"},{"issue":"17","key":"10.1016\/j.neuropharm.2026.110994_bib22","doi-asserted-by":"crossref","DOI":"10.3390\/ijms241713243","article-title":"Calcium dyshomeostasis drives pathophysiology and neuronal demise in age-related neurodegenerative diseases","volume":"24","author":"Griffioen","year":"2023","journal-title":"Int. J. Mol. Sci."},{"issue":"9","key":"10.1016\/j.neuropharm.2026.110994_bib23","doi-asserted-by":"crossref","first-page":"5373","DOI":"10.1074\/jbc.M511560200","article-title":"6-hydroxydopamine-induced apoptosis is mediated via extracellular auto-oxidation and caspase 3-dependent activation of protein kinase Cdelta","volume":"281","author":"Hanrott","year":"2006","journal-title":"J. Biol. Chem."},{"issue":"6","key":"10.1016\/j.neuropharm.2026.110994_bib24","doi-asserted-by":"crossref","first-page":"639","DOI":"10.1007\/s002100100412","article-title":"Species- and agonist-dependent differences in the deactivation-kinetics of P2X7 receptors","volume":"363","author":"Hibell","year":"2001","journal-title":"Naunyn-Schmiedebergs Arch Pharmacol"},{"issue":"6112","key":"10.1016\/j.neuropharm.2026.110994_bib25","doi-asserted-by":"crossref","first-page":"1308","DOI":"10.1126\/science.1228757","article-title":"Crystal structure of the calcium release-activated calcium channel Orai","volume":"338","author":"Hou","year":"2012","journal-title":"Science"},{"issue":"1","key":"10.1016\/j.neuropharm.2026.110994_bib26","doi-asserted-by":"crossref","first-page":"591","DOI":"10.1038\/s41398-021-01724-w","article-title":"Strategies to identify candidate repurposable drugs: COVID-19 treatment as a case example","volume":"11","author":"Imami","year":"2021","journal-title":"Transl. Psychiatry"},{"issue":"1","key":"10.1016\/j.neuropharm.2026.110994_bib27","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1186\/s40478-021-01224-4","article-title":"Reappraisal of metabolic dysfunction in neurodegeneration: focus on mitochondrial function and calcium signaling","volume":"9","author":"Jadiya","year":"2021","journal-title":"Acta Neuropathol. Commun."},{"key":"10.1016\/j.neuropharm.2026.110994_bib28","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2022.1007315","article-title":"Therapeutic drug repositioning with special emphasis on neurodegenerative diseases: threats and issues","volume":"13","author":"Kakoti","year":"2022","journal-title":"Front. Pharmacol."},{"issue":"2","key":"10.1016\/j.neuropharm.2026.110994_bib29","first-page":"CD003735","article-title":"Anticholinergics for symptomatic management of Parkinson's disease","volume":"2002","author":"Katzenschlager","year":"2003","journal-title":"Cochrane Database Syst. Rev."},{"issue":"3","key":"10.1016\/j.neuropharm.2026.110994_bib30","doi-asserted-by":"crossref","first-page":"1680","DOI":"10.1111\/cbdd.13572","article-title":"N(10) -carbonyl-substituted phenothiazines inhibiting lipid peroxidation and associated nitric oxide consumption powerfully protect brain tissue against oxidative stress","volume":"94","author":"Keynes","year":"2019","journal-title":"Chem. Biol. Drug Des."},{"issue":"6","key":"10.1016\/j.neuropharm.2026.110994_bib31","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1179\/135100003225003393","article-title":"Oxidative damage and major depression: the potential antioxidant action of selective serotonin re-uptake inhibitors","volume":"8","author":"Khanzode","year":"2003","journal-title":"Redox Rep."},{"issue":"1","key":"10.1016\/j.neuropharm.2026.110994_bib32","article-title":"Oxidative stress in age-related neurodegenerative diseases: an overview of recent tools and findings","volume":"12","author":"Korovesis","year":"2023","journal-title":"Antioxidants (Basel)"},{"issue":"1","key":"10.1016\/j.neuropharm.2026.110994_bib33","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1002\/glia.24629","article-title":"The antipsychotic chlorpromazine reduces neuroinflammation by inhibiting microglial voltage-gated potassium channels","volume":"73","author":"Lee","year":"2025","journal-title":"Glia"},{"issue":"6","key":"10.1016\/j.neuropharm.2026.110994_bib34","doi-asserted-by":"crossref","first-page":"673","DOI":"10.1085\/jgp.201010484","article-title":"A single lysine in the N-terminal region of store-operated channels is critical for STIM1-mediated gating","volume":"136","author":"Lis","year":"2010","journal-title":"J. Gen. Physiol."},{"key":"10.1016\/j.neuropharm.2026.110994_bib35","article-title":"Unlocking the therapeutic potential of P2X7 receptor: a comprehensive review of its role in neurodegenerative disorders","volume":"15","author":"Liu","year":"2024","journal-title":"Front. Pharmacol."},{"key":"10.1016\/j.neuropharm.2026.110994_bib36","doi-asserted-by":"crossref","first-page":"911","DOI":"10.3389\/fphar.2018.00911","article-title":"Activation of Nrf2\/HO-1 pathway by nardochinoid C inhibits inflammation and oxidative stress in lipopolysaccharide-stimulated macrophages","volume":"9","author":"Luo","year":"2018","journal-title":"Front. Pharmacol."},{"issue":"6","key":"10.1016\/j.neuropharm.2026.110994_bib37","doi-asserted-by":"crossref","first-page":"393","DOI":"10.4103\/ijp.ijp_860_22","article-title":"Translational research: bridging the gap between preclinical and clinical research","volume":"54","author":"Mahalmani","year":"2022","journal-title":"Indian J. Pharmacol."},{"issue":"5","key":"10.1016\/j.neuropharm.2026.110994_bib38","doi-asserted-by":"crossref","first-page":"2644","DOI":"10.1007\/s12035-023-03221-1","article-title":"Chlorpromazine, an inverse agonist of D1R-Like, differentially targets voltage-gated calcium channel (Ca(V)) subtypes in mPFC neurons","volume":"60","author":"McCarthy","year":"2023","journal-title":"Mol. Neurobiol."},{"issue":"7384","key":"10.1016\/j.neuropharm.2026.110994_bib39","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1038\/nature10752","article-title":"Gated regulation of CRAC channel ion selectivity by STIM1","volume":"482","author":"McNally","year":"2012","journal-title":"Nature"},{"issue":"10","key":"10.1016\/j.neuropharm.2026.110994_bib40","article-title":"Targeting Ca(2+) and mitochondrial homeostasis by antipsychotic thioridazine in leukemia cells","volume":"12","author":"Moraes","year":"2022","journal-title":"Life (Basel)"},{"issue":"1","key":"10.1016\/j.neuropharm.2026.110994_bib41","doi-asserted-by":"crossref","first-page":"6662","DOI":"10.1038\/s41467-024-50771-6","article-title":"High-affinity agonism at the P2X(7) receptor is mediated by three residues outside the orthosteric pocket","volume":"15","author":"Oken","year":"2024","journal-title":"Nat. Commun."},{"issue":"10","key":"10.1016\/j.neuropharm.2026.110994_bib42","doi-asserted-by":"crossref","first-page":"4619","DOI":"10.1021\/jf010586o","article-title":"Development and validation of an improved oxygen radical absorbance capacity assay using fluorescein as the fluorescent probe","volume":"49","author":"Ou","year":"2001","journal-title":"J. Agric. Food Chem."},{"issue":"1","key":"10.1016\/j.neuropharm.2026.110994_bib43","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1186\/s13041-025-01211-z","article-title":"Chlorpromazine directly inhibits Kv1.3 channels by facilitating the inactivation of channels","volume":"18","author":"Park","year":"2025","journal-title":"Mol. Brain"},{"key":"10.1016\/j.neuropharm.2026.110994_bib44","doi-asserted-by":"crossref","first-page":"58","DOI":"10.3389\/fphar.2018.00058","article-title":"The molecular determinants of small-molecule ligand binding at P2X receptors","volume":"9","author":"Pasqualetto","year":"2018","journal-title":"Front. Pharmacol."},{"issue":"10","key":"10.1016\/j.neuropharm.2026.110994_bib45","doi-asserted-by":"crossref","first-page":"4290","DOI":"10.1021\/jf0502698","article-title":"Standardized methods for the determination of antioxidant capacity and phenolics in foods and dietary supplements","volume":"53","author":"Prior","year":"2005","journal-title":"J. Agric. Food Chem."},{"issue":"1","key":"10.1016\/j.neuropharm.2026.110994_bib46","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1038\/nrd.2018.168","article-title":"Drug repurposing: progress, challenges and recommendations","volume":"18","author":"Pushpakom","year":"2019","journal-title":"Nat. Rev. Drug Discov."},{"issue":"1","key":"10.1016\/j.neuropharm.2026.110994_bib47","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1186\/s40169-017-0181-2","article-title":"A perspective on multi-target drug discovery and design for complex diseases","volume":"7","author":"Ramsay","year":"2018","journal-title":"Clin. Transl. Med."},{"key":"10.1016\/j.neuropharm.2026.110994_bib48","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1016\/j.maturitas.2020.05.018","article-title":"The World Health Organization (WHO) approach to healthy ageing","volume":"139","author":"Rudnicka","year":"2020","journal-title":"Maturitas"},{"key":"10.1016\/j.neuropharm.2026.110994_bib49","doi-asserted-by":"crossref","first-page":"93","DOI":"10.3389\/fnmol.2020.00093","article-title":"P2X7 receptor antagonism as a potential therapy in amyotrophic lateral sclerosis","volume":"13","author":"Ruiz-Ruiz","year":"2020","journal-title":"Front. Mol. Neurosci."},{"issue":"10284","key":"10.1016\/j.neuropharm.2026.110994_bib50","doi-asserted-by":"crossref","first-page":"1577","DOI":"10.1016\/S0140-6736(20)32205-4","article-title":"Alzheimer's disease","volume":"397","author":"Scheltens","year":"2021","journal-title":"Lancet"},{"issue":"1","key":"10.1016\/j.neuropharm.2026.110994_bib51","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1186\/s13321-017-0212-4","article-title":"Comparative analyses of structural features and scaffold diversity for purchasable compound libraries","volume":"9","author":"Shang","year":"2017","journal-title":"J. Cheminf."},{"issue":"47","key":"10.1016\/j.neuropharm.2026.110994_bib52","doi-asserted-by":"crossref","first-page":"35855","DOI":"10.1074\/jbc.M608247200","article-title":"Stored Ca2+ depletion-induced oligomerization of stromal interaction molecule 1 (STIM1) via the EF-SAM region: an initiation mechanism for capacitive Ca2+ entry","volume":"281","author":"Stathopulos","year":"2006","journal-title":"J. Biol. Chem."},{"issue":"9","key":"10.1016\/j.neuropharm.2026.110994_bib53","doi-asserted-by":"crossref","DOI":"10.3390\/ijms22094771","article-title":"Nitric oxide as a target for phytochemicals in anti-neuroinflammatory prevention therapy","volume":"22","author":"Subedi","year":"2021","journal-title":"Int. J. Mol. Sci."},{"issue":"6","key":"10.1016\/j.neuropharm.2026.110994_bib54","doi-asserted-by":"crossref","first-page":"1437","DOI":"10.1016\/j.cell.2017.10.049","article-title":"A next generation connectivity map: L1000 platform and the first 1,000,000 profiles","volume":"171","author":"Subramanian","year":"2017","journal-title":"Cell"},{"key":"10.1016\/j.neuropharm.2026.110994_bib55","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2022.974849","article-title":"Drug repositioning: a bibliometric analysis","volume":"13","author":"Sun","year":"2022","journal-title":"Front. Pharmacol."},{"key":"10.1016\/j.neuropharm.2026.110994_bib56","doi-asserted-by":"crossref","DOI":"10.1016\/j.ceca.2024.102928","article-title":"Targeting calciumopathy for neuroprotection: focus on calcium channels Cav1, Orai1 and P2X7","volume":"123","author":"Torres-Rico","year":"2024","journal-title":"Cell Calcium"},{"issue":"1","key":"10.1016\/j.neuropharm.2026.110994_bib57","doi-asserted-by":"crossref","first-page":"65","DOI":"10.2174\/157015909787602823","article-title":"Oxidative stress and neurodegenerative diseases: a review of upstream and downstream antioxidant therapeutic options","volume":"7","author":"Uttara","year":"2009","journal-title":"Curr. Neuropharmacol."},{"issue":"10","key":"10.1016\/j.neuropharm.2026.110994_bib58","doi-asserted-by":"crossref","DOI":"10.3390\/cancers12102876","article-title":"Blockage of store-operated Ca(2+) influx by Synta66 is mediated by direct inhibition of the Ca(2+) selective Orai1 pore","volume":"12","author":"Waldherr","year":"2020","journal-title":"Cancers (Basel)"},{"issue":"1","key":"10.1016\/j.neuropharm.2026.110994_bib59","doi-asserted-by":"crossref","first-page":"2772","DOI":"10.1038\/s41467-024-47116-8","article-title":"Structural bases of inhibitory mechanism of Ca(V)1.2 channel inhibitors","volume":"15","author":"Wei","year":"2024","journal-title":"Nat. Commun."},{"issue":"1","key":"10.1016\/j.neuropharm.2026.110994_bib60","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1186\/s12974-024-03057-z","article-title":"P2X7 receptor antagonists modulate experimental autoimmune neuritis via regulation of NLRP3 inflammasome activation and Th17 and Th1 cell differentiation","volume":"21","author":"Xie","year":"2024","journal-title":"J. Neuroinflammation"},{"issue":"2","key":"10.1016\/j.neuropharm.2026.110994_bib61","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1039\/C5MB00781J","article-title":"Binding mechanisms of 1,4-dihydropyridine derivatives to L-type calcium channel Cav1.2: a molecular modeling study","volume":"12","author":"Xu","year":"2016","journal-title":"Mol. Biosyst."},{"issue":"6","key":"10.1016\/j.neuropharm.2026.110994_bib62","doi-asserted-by":"crossref","first-page":"1495","DOI":"10.1016\/j.cell.2019.04.043","article-title":"Molecular basis for ligand modulation of a mammalian voltage-gated Ca(2+) channel","volume":"177","author":"Zhao","year":"2019","journal-title":"Cell"},{"key":"10.1016\/j.neuropharm.2026.110994_bib63","doi-asserted-by":"crossref","DOI":"10.3389\/fnana.2022.910427","article-title":"Deconvoluting the complexity of Reactive Oxygen Species (ROS) in neurodegenerative diseases","volume":"16","author":"Zhou","year":"2022","journal-title":"Front. Neuroanat."},{"key":"10.1016\/j.neuropharm.2026.110994_bib64","article-title":"Nanoparticles: a hope for the treatment of inflammation in CNS","volume":"12","author":"Zhu","year":"2021","journal-title":"Front. Pharmacol."},{"issue":"5","key":"10.1016\/j.neuropharm.2026.110994_bib65","doi-asserted-by":"crossref","first-page":"1256","DOI":"10.1152\/japplphysiol.01124.2010","article-title":"Role of STIM1\/Orai1-mediated store-operated Ca(2)(+) entry in airway smooth muscle cell proliferation","volume":"2011","author":"Zou","year":"1985","journal-title":"J. Appl. Physiol."}],"container-title":["Neuropharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S002839082600167X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S002839082600167X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,11,12]],"date-time":"2026-11-12T09:34:36Z","timestamp":1794476076000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S002839082600167X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9]]},"references-count":65,"alternative-id":["S002839082600167X"],"URL":"https:\/\/doi.org\/10.1016\/j.neuropharm.2026.110994","relation":{},"ISSN":["0028-3908"],"issn-type":[{"value":"0028-3908","type":"print"}],"subject":[],"published":{"date-parts":[[2026,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Unexpected mechanisms of repurposed drugs in the pathogenic pathways of neurodegenerative diseases. Discovering new neuroprotective therapies in cellular models","name":"articletitle","label":"Article Title"},{"value":"Neuropharmacology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.neuropharm.2026.110994","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier Ltd. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"110994"}}